Navigation Links
Biocon To Shift Focus On Innovation To Accelerate Growth

Biocon Ltd, India's largest biotechnology firm, has made a paradigm shift from being a generic drug manufacturer to innovation to drive its future growth aggressively. //

"We are rapidly transforming from a generics API (active pharmaceutical ingredients) manufacturer into an innovator for developing a robust pipeline of new molecules.

"We believe this strategy will deliver strong and sustainable growth in the future," Biocon chairperson Kiran Mazumdar-Shaw told reporters here Thursday.

Giving the company's outlook for the current fiscal (2006-07), Shaw said the year ahead would continue to be challenging due to uncertainties in market conditions and the impact of depreciation at its new facilities in the biotech park.

"We believe our balanced portfolio of products and services will deliver superior shareholder value over the medium and long-term. We expect our insulin products to gain substantial market share both in India and overseas markets," Shaw said.

The company, however, did not give any revenue guidance figure for the current fiscal or its first quarter (April-June) of FY 2007 as the biotech sector is evaluated on a medium to long-term basis, given the gestational nature of its R&D investments and regulatory time lines.

According to Biocon chief operating officer (COO) Arun Chandavarkar, the company's innovation strategy was built on in-house capabilities, proprietary technologies and a broad array of licensing and alliance partners the world over.

"Our focus on IP (intellectual property) and technology continues to be a strong differentiator. We have invested Rs.760 million in R&D capabilities during fiscal 2005-06, which is an increase of 76 percent over the previous fiscal (2004-05)," Chandavarkar said.

On the acquisition of the US-based Nobex portfolio for $5 million, Shaw said the company would leverage the proprietary intellectual (IP) assets through a combination of in-ho use development, licensing and co-development.

The strategic acquisition gives Biocon access to about 300 granted or filed patents of Nobex in oral peptide delivery in the metabolic and cardiovascular segment.

"Besides full ownership of oral insulin and oral BNP programmes, we will have access to products in early phase I & II development such as oral calcitonin, oral para thyroid hormone (PTH) and Apaza, an oral small molecule for inflammatory bowel diseases," Shaw pointed out.

As part of its long-term strategy, the company plans to build bio-similar therapeutic protein franchise through in-house development and strategic collaborations.

With the commissioning of the multi-product biologics facility (Biopharmaceuticals) this month in its Biotech Park, the company is gearing up to manufacture a range of monoclonal anti-bodies and other recombinant therapeutic products.

"We have completed registration enabling clinical trials for our therapeutic drug (BIOMAb EGFR) to treat neck and head cancers.

Investigational new drug application (IND) for diabetes oral insulin is on track for filing later this year," Chandavakar added.

Meanwhile, the company has entered into an agreement with the Sweden-based Karolinska Institute to partner in product development, joint research programmes and scientific symposia in India.

During the fiscal year 2005-06, Biocon posted a consolidated income of Rs.7.93 billion and net profit of Rs.1.74 billion.

As part of its capital expenditure, Biocon invested Rs.6.5 billion over the last two years in expanding its existing capacities and setting up new manufacturing facilities for its two subsidiaries - Clinigene and Syngene.

--Edited IANS
'"/>




Related medicine news :

1. Biocon to colloborate for development of Oral peptide drugs for heart diseases.
2. Biocon To Raise Its Investment In Scotland
3. Kalam Dedicates New Cancer Drug Developed By Biocon
4. Bayer to Market Biocon Insulin in China
5. Biocon Launches Anti-Cancer Drug
6. Biocon to Launch Anti-arthritis Drug
7. Biocon Unveils Renal Therapies for Kidney Disorders
8. Biocon Net Profit Up by 15 Percent for Fiscal Year
9. Govt to Shift its Focus From Curative to Preventive Mode of Healthcare
10. Sex Ends as Seasons Shift and Kisspeptin Levels Plummet
11. Doctors Advise Shifting of Ailing Soren
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/25/2017)... OK (PRWEB) , ... July 25, 2017 , ... ... proud to announce the launch of their partnership to provide the Pharmacist ... the first pharmacy-focused platform in the country with the ability to develop the ...
(Date:7/25/2017)... ... July 25, 2017 , ... Therachat ... will be exhibiting and providing demos of its smart journaling platform at the ... Center in Washington D.C. from August 3-6, 2017. , The APA Annual Convention ...
(Date:7/25/2017)... , ... July 25, 2017 , ... ... ATM provider in the United States, today announced its partnership with financial technology ... , The foundation of the solution lies within Hyosung’s superior ATMs, assisted ...
(Date:7/25/2017)... Jacksonville, Fla. (PRWEB) , ... July 25, 2017 , ... ... employee and father Ezra Clark is taking advantage of a new benefit for employees ... “It really means a lot that the company supports me and other employees as ...
(Date:7/25/2017)... TX (PRWEB) , ... July 25, 2017 , ... SignatureCare ... emergencies in the Austin, TX area 24 Hours a day. , The ... Austin, TX. , “We’ve been open four months now and things are running ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... and CAMBRIDGE, Massachusetts , July 25, 2017 ... repurposing drugs to treat rare nervous system diseases, has concluded ... develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). ... very promising results in a Phase 2 study conducted in ... office in the United States ...
(Date:7/24/2017)... July 24, 2017 IBM (NYSE: IBM ) ... Quadrant for Solid-State Arrays (SSA) for the fourth year in ... According to Gartner, "Vendors in the Leaders quadrant have the ... Vision. A vendor in the Leaders quadrant has the market ... the acceptance of new technologies. These vendors demonstrate a clear ...
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 /PRNewswire/ ... University of Alberta in Edmonton, Canada ... partner journal, Schizophrenia 1 , demonstrating that AI ... schizophrenia with 74% accuracy. This retrospective analysis also ... symptoms in schizophrenia patients with significant correlation, based ...
Breaking Medicine Technology: